top of page
OUR MISSION
Engineering specialized protein combinations to redefine clarity and precision in immune oncology for patients globally.
At Proteocent Therapeutics, we are dedicated to advancing the future of biologics. By focusing on protein-centric design, we aim to deliver next-generation therapeutic efficacy through scientific rigor and innovative engineering.
Scientific Leadership
Dr. Mohit Kumar
Founder & CEO
PhD in Chemical Engineering from Rutgers and Postdoctoral Research Fellow at Harvard Medical School. Expert in antibody therapeutics and protein-centric biologics.
bottom of page